Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-04-11

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the biomarker profile in diabetic macular edema patients in response to intravitreal aflibercept injection. Patients with diabetic macular edema who meet study requirements will receive monthly intravitreal injections of aflibercept as approved by FDA for a period of 6 months. A small quantity of fluid will be removed from the vitreous at each injection for laboratory evaluation of biomarkers present before, during and after treatment with aflibercept.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection

NCT03453281

Diabetic Macular Edema Diabetic Retinopathy Clinically Significant Macular Edema

COMPLETED PHASE4

A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema

NCT05511038

Diabetic Macular Edema

COMPLETED PHASE4

Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

NCT01363440

Diabetic Macular Edema

COMPLETED PHASE3

Follow up of Diabetic Macular Edema Treated by Aflibercept (Eylea®) With OCT-Angiography

NCT03783832

Diabetic Macular Edema

UNKNOWN

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

NCT07118670

Proliferative Diabetic Retinopathy (PDR)

NOT_YET_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study objective is to better understand the pathophysiology of diabetic macular edema (DME) by defining the factors that participate in the disease process or may be good biomarkers for disease progression. Study will investigate the temporal relationship between the course of treatment with anti-VEGF therapy and levels of candidate biomarkers previously identified to determine which biomarkers are affected by anti-VEGF therapy with aflibercept. Study will correlate response to therapy to particular biomarkers and attempt to identify those associated with resistance to therapy for DME. Biomarker data will be correlated with serial clinical evaluation of disease progression. 40 subjects with clinically significant DME who plan to undergo anti-VEGF therapy will be treated with intravitreal aflibercept monthly for 6 months. At each visit aqueous humor will be collected and stored (6 samples per patient). At termination of study all specimens will be analyzed for biomarkers identified from previous studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aflibercept Injection [Eylea]

Intravitreal injection aflibercept

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Current diagnosis type 1 or type 2 diabetes
* Clinical DME as assessed by OCT
* Well controlled glaucoma on medications but not on prostaglandin analogues
* Mild Age Related Macular Degeneration (AMD)
* Visual acuity between 73 and 5 ETDRS letters (20/40 -20/800 on eye chart)
* Willing and able to participate and to comply with clinic visits and procedures
* Provide signed informed consent

Exclusion Criteria

* Unwillingness to participate or inability to understand or sign informed consent
* Poor eye fluid that would preclude adequate testing
* Prior intraocular treatment with anti-VEGF or focal laser treatment within 90 days
* Corticosteroid injections within 120 days
* Active proliferative diabetic retinopathy
* Intraocular pressure greater than 25 mm Hg
* Any previous vitrectomy surgery
* Current use of systemic anti-VEGF agents
* Shallow anterior eye chamber in eye with natural lens
* Non-diabetic related macular swelling (retinal vein occlusion)
* History of ocular disease
* Systemic disease other than diabetes mellitus
* Pregnant or breast feeding women
* Sexually active men or women of childbearing potential who are unwilling to practice adequate birth control during study

Minimum Eligible Age

18 Years

Maximum Eligible Age

89 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes